Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review
Zhenwang Nie,Tao Sun,Fangcheng Zhao
DOI: https://doi.org/10.2147/IDR.S362946
2022-08-12
Infection and Drug Resistance
Abstract:Zhenwang Nie, &ast Tao Sun, &ast Fangcheng Zhao Department of Infectious Disease, The Second Hospital of Dalian Medical University, Dalian, Liaoning, 116023, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fangcheng Zhao, Department of Infectious Disease, The Second Hospital of Dalian Medical University, No. 467, Zhongshan Road, Shahekou District, Dalian, Liaoning, 116023, People's Republic of China, Tel +86-13677977862, Email Objective: To investigate the efficacy and safety of antiviral drugs in the treatment of coronavirus disease 2019 (COVID-19). Methods: All clinical trials of antiviral drug treatment for COVID-19 from December 2019 to December 2021 in CNKI, PubMed, Embase, Wanfang and VIP databases were searched by computer, and the results were systematically reviewed. Results: A total of 21 studies were included, including 5 randomized controlled studies, 5 non-randomized controlled studies, 3 retrospective cohort studies, 6 retrospective case series studies, and 2 observational studies, with a total of 2118 patients. The evaluated drugs included Ridzevir, Lopinavir/Ritonavir, Jingluwa, Fapiravi, Abidor, Danorivir, and interferon α. The evaluated antiviral drugs did not show superior efficacy for COVID-19 in clinical trials. In terms of safety, particular attention needs to be paid to the gastrointestinal side effects of lopinavir/ritonavir and the serious side effects of redsivir. Conclusion: There is no specific drug. Antiviral drugs have a greater therapeutic benefit for mild and usual patients, and in severe patients, lopinavir/ritonavir may not be effective. For critically ill patients, adefovir or more than two antiviral drugs can be used early. Antiviral drugs combined with traditional Chinese medicine treatment is effective. In view of the safety of the drug, it is necessary to consider the increase of serum uric acid caused by fapravi, the increase of bilirubin caused by abidol, and the gastrointestinal reactions of pitavir. In addition, other adverse reactions should also be noted. Keywords: COVID-19, safety, antiviral drugs Coronavirus Disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread in many countries and regions around the world since 2019. At present, more than 250 million people have been infected and millions have died. Although vaccination and isolation of patients have been implemented in various countries, more than 100,000 new patients are added daily. Previous studies have shown that about 19% of COVID-19 patients develop into severe or critical diseases, 1 and the mortality rate is more than 15%. 2 In addition to severe lung injury and functional changes, patients will also lead to complications such as liver, nervous system and gastrointestinal tract. Single drug may not achieve therapeutic effect. At the same time, the combined use of multiple drugs will increase the risk of drug interactions, resulting in reduced or increased drug exposure, affecting the efficacy and safety of treatment. Therefore, drug selection and diagnosis and treatment plan determination have great challenges. 3 Treatment of COVID-19 has not yet been defined. Early antiviral therapy is based on the experience of fighting SARS and MARS, and a large number of clinical trials are carried out to verify the efficacy of drugs. 4 China National Health Commission has issued eight editions of new coronavirus pneumonia diagnosis and treatment programs. Interferon, lopinavir/ritonavir, ribavirin, chloroch and abidol are among the recommended drugs for the treatment programme. 5 Currently, according to various versions of our pneumonia treatment protocols and studies for novel coronavirus infections, 6 antiviral drugs such as ribavirin, abirater and lopinavir are included in the treatment of COVID-19 in China. Redsivir is currently in clinical trials and has not been put into use on its own, but only as an adjuvant drug in conjunction with it. NIH guidelines indicate that the antiviral drugs currently available as therapeutic agents in the US are Redsivir, Paxlovid and Monupivir. Meanwhile, after two years of clinical research and practice, more relevant results have been published. Although there are many reviews that have done the same work we have done, searching for and summarising the effectiveness and safety of antiviral drugs, the main drugs analysed and the focus of each review varies and does not provide a detailed summary of the effectiveness and safety of all drugs, and over time, new characteristics of the physicochemical properties of some drugs are identified. In order to obtain a more comprehensive and higher level -Abstract Truncated-
pharmacology & pharmacy,infectious diseases